Advertisement
Screener

Skye Bioscience, Inc. (SKYE) Operating Lease Cost

2.8 / 5 stars · 68/120 Roast Me

Skye Bioscience, Inc. Operating Lease Cost

Skye Bioscience, Inc. (SKYE) reported Operating Lease Cost of $207.40 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-10.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:OperatingLeaseCost · last filed 2026-03-10

  • Skye Bioscience, Inc. operating lease, cost for the quarter ending 2023-12-31 was $26.08K, a 15.00% increase year-over-year.
  • Skye Bioscience, Inc. operating lease, cost for the quarter ending 2023-09-30 was $26.08K, a 15.00% increase year-over-year.
  • Skye Bioscience, Inc. operating lease, cost for the quarter ending 2023-06-30 was $22.68K, a 0.00% change year-over-year.
  • Skye Bioscience, Inc. operating lease, cost for the quarter ending 2023-03-31 was $23.16K, a 2.13% increase year-over-year.
  • Skye Bioscience, Inc. operating lease, cost for fiscal 2025 was $207.40K, a 58.74% increase from fiscal 2024.
  • Skye Bioscience, Inc. operating lease, cost for fiscal 2024 was $130.66K, a 33.34% increase from fiscal 2023.
  • Skye Bioscience, Inc. operating lease, cost for fiscal 2023 was $97.99K, a 8.03% increase from fiscal 2022.
  • Skye Bioscience, Inc. operating lease, cost for fiscal 2022 was $90.70K, a 200.00% increase from fiscal 2021.
Period endOperating Lease, Cost 3 monthOperating Lease, Cost 6 monthOperating Lease, Cost 9 monthOperating Lease, Cost 12 month
2025-12-31$207.40K
10-K · filed 2026-03-10
2024-12-31$130.66K
10-K · filed 2026-03-10
2023-12-31$26.08K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20
$52.15K
derived: sum of 2 quarters · filed 2025-03-20
$74.83K
derived: sum of 3 quarters · filed 2025-03-20
$97.99K
10-K · filed 2025-03-20
2023-09-30$26.08K
10-Q · filed 2023-11-14
$48.75K
derived: sum of 2 quarters · filed 2023-11-14
$71.91K
10-Q · filed 2023-11-14
$94.58K
derived: sum of 4 quarters · filed 2024-03-22
2023-06-30$22.68K
10-Q · filed 2023-08-07
$45.83K
10-Q · filed 2023-08-07
$68.51K
derived: sum of 3 quarters · filed 2024-03-22
$91.18K
derived: sum of 4 quarters · filed 2024-03-22
2023-03-31$23.16K
10-Q · filed 2023-05-12
$45.83K
derived: sum of 2 quarters · filed 2024-03-22
$68.51K
derived: sum of 3 quarters · filed 2024-03-22
$91.18K
derived: sum of 4 quarters · filed 2024-03-22
2022-12-31$22.68K
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-22
$45.35K
derived: sum of 2 quarters · filed 2024-03-22
$68.03K
derived: sum of 3 quarters · filed 2024-03-22
$90.70K
10-K · filed 2024-03-22
2022-09-30$22.68K
10-Q · filed 2023-11-14
$45.35K
derived: sum of 2 quarters · filed 2023-11-14
$68.03K
10-Q · filed 2023-11-14
$90.70K
derived: sum of 4 quarters · filed 2023-11-14
2022-06-30$22.68K
10-Q · filed 2023-08-07
$45.35K
10-Q · filed 2023-08-07
$68.03K
derived: sum of 3 quarters · filed 2023-08-07
$75.58K
derived: sum of 4 quarters · filed 2023-08-07
2022-03-31$22.68K
10-Q · filed 2023-05-12
$45.35K
derived: sum of 2 quarters · filed 2023-05-12
$52.91K
derived: sum of 3 quarters · filed 2023-05-12
2021-12-31$22.68K
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31
$30.23K
derived: sum of 2 quarters · filed 2023-03-31
$30.23K
10-K · filed 2023-03-31
2021-09-30$7.56K
10-Q · filed 2022-11-14
$7.56K
10-Q · filed 2022-11-14

Similar stocks

Stock NameCountryMarket CapPE Ratio
CalciMedica, Inc. (CALC)United States$0.061B-1.42
TALPHERA, INC. (TLPH)United States$0.060B
Boundless Bio, Inc. (BOLD)United States$0.059B-0.88
NOMAD POWER SOLUTIONS, INC. (NMAD)United States$0.058B
Rein Therapeutics, Inc. (RNTX)United States$0.063B-1.76
HYPERION DEFI, INC. (HYPD)United States$0.065B
Annovis Bio, Inc. (ANVS)United States$0.056B-1.58
XBiotech Inc. (XBIT)United States$0.066B-1.56
HERON THERAPEUTICS, INC. /DE/ (HRTX)United States$0.055B-2.38
Clene Inc. (CLNN)United States$0.054B-1.99